Key facts
- It has raised $4.7M; the latest was Later Stage VC ($4.7M) in Jul 2025.
- Notable investors include 01Booster, Asahi Group Holdings, China Aircraft Leasing, No. 4 Hokuetsu Regional Revitalization Investment Business Limited Liability Partnership, Sakurajyuji — 7 tracked in total.
- Status: Acquired/Merged (Operating Subsidiary).
- ·The complete investor list — 7 names
- ·Watchlist + deal alerts for ReEir
- ·The full record, as it builds
Funding rounds
No funding rounds for ReEir are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ReEir
Developer of a regenerative medicine platform designed to restore the bond between patients and society by treating serious illnesses with cell therapies derived from blood samples. The company offers innovative, simple, blood-based treatments, enabling patients with severe conditions to regain health and rejoin society, fostering new hope for life.
- Sector
- Healthcare
- HQ
- Minato-ku, Japan
- Founded
- 2017
- Website
- re-eir.com/
- Ownership
- Acquired/Merged (Operating Subsidiary)
ReEir doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ReEir shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ReEir in its N-PORT filings yet. We sweep new filings monthly.